help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Published ahead of print on July 13, 2006, doi:10.1164/rccm.200603-380OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200603-380OCv1
174/9/990    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Abroug, F.
Right arrow Articles by Knani, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abroug, F.
Right arrow Articles by Knani, J.
American Journal of Respiratory and Critical Care Medicine Vol 174. pp. 990-996, (2006)
© 2006 American Thoracic Society
doi: 10.1164/rccm.200603-380OC


Original Article

Association of Left-Heart Dysfunction with Severe Exacerbation of Chronic Obstructive Pulmonary Disease

Diagnostic Performance of Cardiac Biomarkers

Fekri Abroug, Lamia Ouanes-Besbes, Noureddine Nciri, Noura Sellami, Faouzi Addad, Khaldoun Ben Hamda, Adel Ben Amor, Mohamed F. Najjar and Jalel Knani

Intensive Care Unit, Department of Cardiology, and Biochemistry Laboratory, Fattouma Bourguiba University Hospital, Monastir, Tunisia

Correspondence and requests for reprints should be addressed to Fekri Abroug, M.D., ICU, CHU F. Bourguiba, 5000 Monastir, Tunisia. E-mail: f.abroug{at}rns.tn

Rationale: Cardiac biomarkers are used to distinguish acute dyspnea due to left-heart dysfunction from that of pulmonary origin. However, they have not been assessed in the specific setting of acute exacerbation of chronic obstructive pulmonary disease (AECOPD), where they might be released without left-heart impairment.

Objective: To assess the accuracy of troponin T and of amino-terminal pro–brain natriuretic peptide (NT-proBNP) in the diagnosis of AECOPD associated with left ventricular (LV) dysfunction.

Methods: Both biomarkers were measured in 148 consecutive patients on intensive care unit admission for AECOPD. A panel of physicians adjudicated blindly the cause of AECOPD to be unlikely, possibly associated, or definitely associated with LV dysfunction.

Measurements and Main Results: The final diagnosis was AECOPD definitely associated with acute left-heart dysfunction in 31.1%, possibly associated with LV dysfunction in 13.5%, and probably not associated with LV dysfunction in 55.4%. Both NT-proBNP and troponin T levels were significantly different among the three groups. The area under the receiver operating characteristic curve was greater for NT-proBNP (0.95 vs. 0.67). A cutoff of 1,000 pg/ml was accurate to rule out left-heart involvement in AECOPD (sensitivity, 94%; negative predictive value, 94%; negative likelihood ratio, 0.08). A cutoff of 2,500 pg/ml had the best operating characteristics to rule in the diagnosis (positive likelihood ratio, 5.16). Left-heart involvement in AECOPD was the only variable independently associated with increased secretion of NT-proBNP (odds ratio, 74; 95% confidence interval, 15–375; p = 0.0001).

Conclusion: NT-proBNP and troponin T are useful in excluding AECOPD associated with left ventricular dysfunction. NT-proBNP was the more accurate of the two.

Key Words: B-type natriuretic peptide • chronic obstructive pulmonary disease • exacerbation • left ventricular dysfunction • troponin




This article has been cited by other articles:


Home page
Proc Am Thorac SocHome page
N. MacIntyre and Y. C. Huang
Acute Exacerbations and Respiratory Failure in Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, May 1, 2008; 5(4): 530 - 535.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
F. J. Martinez
Pathogen-directed Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, December 1, 2007; 4(8): 647 - 658.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
K. F. Rabe, B. Beghe, F. Luppi, and L. M. Fabbri
Update in Chronic Obstructive Pulmonary Disease 2006
Am. J. Respir. Crit. Care Med., June 15, 2007; 175(12): 1222 - 1232.
[Full Text] [PDF]


Home page
ChestHome page
G. B. J. Mancini
Clarion Call for Trials Assessing "Cardiopulmonary" Agents To Reduce Morbidity and Mortality in Inflammatory Lung Diseases
Chest, April 1, 2007; 131(4): 950 - 951.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
C. Ceconi and R. Ferrari
One heart, two lungs together forever.
Am. J. Respir. Crit. Care Med., November 1, 2006; 174(9): 962 - 963.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2006 American Thoracic Society
  ATS State of the Art 2009